Caribou Biosciences Inc. (CRBU) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Caribou Biosciences Inc. (NASDAQ: CRBU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.45 (-9.07% 1D, market cap $47.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRBU ranks #554 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRBU carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TIL (Instil Bio Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and LONA (LeonaBio Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, CRBU leads on earnings multiple (N/A) while CRBU leads on capital efficiency (-35.0% ROIC).
Per CRBU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001619856), Caribou Biosciences Inc. generated $11.2M in revenue (+11.7% YoY), -$148.1M in net income, and -$112.4M in free cash flow against $175.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While CRBU currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.07) and Max Pain ($0.47) forces dealer call-delta covering toward $3.72.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Caribou Biosciences Inc. (CRBU) dropped -9.07% to $0.45, trading at 2% of its 52-week range ($0.41 – $3.54). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Caribou Biosciences is back in focus after fair value estimates shifted from about US$11.86 to US$5.75 per share, echoing recent price target resets across Wall Street coverage. Analysts are reacting to halted clinical p
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRBU today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRBU. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Caribou Biosciences Inc. (CRBU) ranks #554 by composite RQD confidence (43/100, grade D-) and #757 by equity capitalization ($47.7M). Within this direct 5-issuer industry benchmark cohort, CRBU leads on earnings valuation at N/A trailing P/E, while CRBU leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with CRBU at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRBU
ACTIVE
Caribou Biosciences Inc. | D- | 43/100 | — | — | -35.0% | -9.07% | $47.7M | Benchmark Subject |
| TIL Instil Bio Inc. | D | 51/100 | — | — | -35.0% | +0.52% | $46.3M | /til-vs-crbu → |
| LONA LeonaBio Inc. | D- | 42/100 | — | — | -35.0% | -1.01% | $46.3M | /lona-vs-crbu → |
| IMA ImageneBio Inc. | E | 24/100 | — | — | -35.0% | -3.57% | $46.0M | /ima-vs-crbu → |
| KLRS Kalaris Therapeutics Inc. | D | 46/100 | — | — | -35.0% | +5.97% | $50.7M | /klrs-vs-crbu → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Caribou Biosciences Inc. (CRBU) reported GAAP revenue of $11.2M (+11.7% vs. FY2024 revenue of $10.0M , and -67.6% cumulative change since FY2023) , GAAP net income of -$148.1M, operating cash flow of -$111.0M, and free cash flow of -$112.4M (+21.5% YoY). On the balance sheet, CRBU closed FY2025 with $175.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $11.2M | -$148.1M | -$111.0M | -$112.4M | $175.4M | — |
| FY2024 (FY) | 2024-12-31 | $10.0M | -$149.1M | -$138.2M | -$143.1M | $313.3M | — |
| FY2023 (FY) | 2023-12-31 | $34.5M | -$102.1M | -$93.3M | -$93.3M | — | — |
As of 2026-11-01, Caribou Biosciences Inc. (NASDAQ: CRBU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.45 (-9.07% 1D, market cap $47.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRBU ranks #554 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRBU carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TIL (Instil Bio Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and LONA (LeonaBio Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, CRBU leads on earnings multiple (N/A) while CRBU leads on capital efficiency (-35.0% ROIC).
Per CRBU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001619856), Caribou Biosciences Inc. generated $11.2M in revenue (+11.7% YoY), -$148.1M in net income, and -$112.4M in free cash flow against $175.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CRBU last traded at $0.45 (-9.07% on volume of 2,837,744 shares), positioning the stock -57.94% below its 50-day simple moving average ($1.07) and -72.39% below its 200-day simple moving average ($1.63). Across its 52-week range of $0.41 to $3.54, CRBU sits at the 1.3% percentile with a 14-day RSI of 23.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.51).
Why CRBU Stock dropped -9.07% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).